ArticleEye (London, England)2021
Safety and efficacy of repeated crosslinking assisted by transepithelial double-cycle iontophoresis in keratoconus progression after primary corneal crosslinking.
Article in Eye (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Transepithelial corneal cross-linking: a review.International ophthalmology · 2026Review
- One-Year Visual, Refractive, Tomographic, and Aberrometric Outcomes of Repeat Corneal Collagen Crosslinking in Eyes with Progressive Keratoconus.Beyoglu eye journal · 2026Article
- Clinical Outcomes of Repeated Corneal Crosslinking for Progressive Keratoconus After Failure of Primary Procedure; Safety and Efficacy at 12-Month Follow-Up.Ophthalmology and therapy · 2025Article
- Digital transformation of care for keratoconus patients: ML modeling structural outcomes of corneal collagen cross-linking.Frontiers in medicine · 2025Article
- Investigation of Potential Crucial Genes and Key Pathways in Keratoconus: An Analysis of Gene Expression Omnibus Data.Biochemical genetics · 2023Article
- Vitamin D Supplementation Impacts Systemic Biomarkers of Collagen Degradation and Copper Metabolism in Patients With Keratoconus.Translational vision science & technology · 2022Observational
- Pediatric Crosslinking: Current Protocols and Approach.Ophthalmology and therapy · 2022Review
- Anterior pituitary, sex hormones, and keratoconus: Beyond traditional targets.Progress in retinal and eye research · 2022Article
- Identification of Key Genes and Molecular Pathways in Keratoconus: Integrating Text Mining and Bioinformatics Analysis.BioMed research international · 2022Article
- Recent Advances in Photodynamic Therapy against Fungal Keratitis.Pharmaceutics · 2021Review
- Paediatric cornea crosslinking current strategies: A review.Advances in ophthalmology practice and researchReview
- Scratch beneath the surface.Oman journal of ophthalmologyArticle
- Repeated corneal crosslinking for progressive keratoconus: efficiency and safety.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the safety and efficacy of repeated corneal collagen crosslinking assisted by transepithelial double-cycle iontophoresis (DI-CXL) in the management of keratoconus progression after primary CXL.
methodsA retrospective analysis was conducted in the patients who underwent repeated CXL between 2016 and 2018. These patients were treated with DI-CXL if keratoconus progression was confirmed after primary CXL. Scoring of ocular pain and corneal epithelial damage, visual acuity, corneal tomography, in vivo corneal confocal microscopy (IVCM) was performed before and at 3, 6, 12, and 24 months after DI-CXL.
resultsOverall, 21 eyes of 12 patients (mean age 17.3 ± 1.9 years) were included in this study. Before DI-CXL, an average increase of 4.26 D in K
conclusionDI-CXL is safe and effective as a good alternative in stabilizing keratoconus progression after primary CXL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.